Bellicum Pharmaceuticals (BLCM) Trading Down 5.8%

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)’s share price traded down 5.8% on Tuesday . The stock traded as low as $8.83 and last traded at $8.86. 554,130 shares were traded during trading, an increase of 9% from the average session volume of 506,105 shares. The stock had previously closed at $9.41.

Several equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price objective on the stock in a report on Wednesday. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. Raymond James Financial reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Finally, Jefferies Group reiterated a “buy” rating and set a $16.00 price objective on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $23.50.

The company has a market cap of $295.05, a P/E ratio of -2.97 and a beta of 1.18. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. The company’s revenue was up 18.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.66) EPS. analysts expect that Bellicum Pharmaceuticals, Inc. will post -2.93 earnings per share for the current year.

In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The stock was sold at an average price of $9.33, for a total value of $159,701.61. Following the sale, the chief financial officer now owns 31,585 shares in the company, valued at approximately $294,688.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Alan A. Musso sold 6,206 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $9.89, for a total value of $61,377.34. The disclosure for this sale can be found here. Insiders own 18.77% of the company’s stock.

Large investors have recently bought and sold shares of the business. Voya Investment Management LLC acquired a new position in shares of Bellicum Pharmaceuticals during the 2nd quarter worth approximately $132,000. Commonwealth Equity Services Inc acquired a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter worth approximately $142,000. Cubist Systematic Strategies LLC acquired a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter worth approximately $164,000. Nationwide Fund Advisors increased its position in shares of Bellicum Pharmaceuticals by 30.4% during the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,620 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Bellicum Pharmaceuticals during the 3rd quarter worth approximately $189,000. 55.28% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.com-unik.info/2018/01/11/bellicum-pharmaceuticals-blcm-trading-down-5-8.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

What are top analysts saying about Bellicum Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellicum Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit